BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report ; volume:18 ; number:1 ; day:28 ; month:9 ; year:2024 ; pages:1-9 ; date:12.2024
Journal of medical case reports ; 18, Heft 1 (28.9.2024), 1-9, 12.2024
- Urheber
-
Ngelangel, Corazon A.
Sy, Florge Francis
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13256-024-04773-z
- URN
-
urn:nbn:de:101:1-2411292109458.873554858651
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ngelangel, Corazon A.
- Sy, Florge Francis
- SpringerLink (Online service)
Ähnliche Objekte (12)
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma